Last reviewed · How we verify

NCT03992651: CTCO

Optical Transcutaneous Sensors of Capnia and Oxygenation

Completed NA Last updated 29 December 2025
What this trial tests

NA trial testing Measurements of capnia and tissue oxygenation by optical transcutaneous sensors in Blood Gas Monitoring, Transcutaneous in 20 participants. Completed in 11 October 2019.

Timeline
12 June 2019
Primary endpoint
13 June 2019
11 October 2019

Quick facts

Lead sponsorUniversity Hospital, Grenoble
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposediagnostic
Enrollment20
Start date12 June 2019
Primary completion13 June 2019
Estimated completion11 October 2019
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

University Hospital, Grenoble

Who can join

Adults 18 to 50, any sex, with Blood Gas Monitoring, Transcutaneous. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims at validating new optical transcutaneous sensors to evaluate tissue capnia (CO2 partial pressure) and oxygenation (blood oxygen saturation) by comparing them to standard laboratory measurements (end tidal CO2 measurements and oxygen saturation by near-infrared spectroscopy).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Contact, high-resolution spatial diffuse reflectance imaging system for skin condition diagnosis: a first-in-human clinical trial.
    Koenig A, Petitdidier N, Grateau H, Characoun S, et al · · 2021 · cited 2× · PMID 33515218 · DOI 10.1117/1.jbo.26.1.012706

Verify or expand the search:

Other University Hospital, Grenoble trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03992651.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing